作者
David A Reardon, Prafulla C Gokhale, Sarah R Klein, Keith L Ligon, Scott J Rodig, Shakti H Ramkissoon, Kristen L Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y Wen, Annick D Van Den Abbeele, F Stephen Hodi, Lei Qin, Nancy E Kohl, Arlene H Sharpe, Glenn Dranoff, Gordon J Freeman
发表日期
2016/2/1
期刊
Cancer immunology research
卷号
4
期号
2
页码范围
124-135
出版商
American Association for Cancer Research
简介
Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable remissions across a spectrum of malignancies. Combinatorial regimens blocking complementary immune checkpoints further enhance the therapeutic benefit. The activity of these agents for patients with glioblastoma, a generally lethal primary brain tumor associated with significant systemic and microenvironmental immunosuppression, is not known. We therefore systematically evaluated the antitumor efficacy of murine antibodies targeting a broad panel of immune checkpoint molecules, including CTLA-4, PD-1, PD-L1, and PD-L2 when administered as single-agent therapy and in combinatorial regimens against an orthotopic, immunocompetent murine glioblastoma model. In these experiments, we observed long-term tumor-free …
引用总数
201620172018201920202021202220232024193745466363595547
学术搜索中的文章